Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
pharmafile | September 13, 2018 | News story | Research and Development | Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to its Interleukin-23 (IL-23)-targeting therapy Tremfya (guselkumab) in patients with moderate to severe plaque psoriasis.
Revealed at the European Academy of Dermatology and Venereology in Paris, the data showed that switching to Tremfya after an inadequate response to Abbvie’s Humira (adalimumab) led to improvements in long-term patient-reported outcomes (PROs).
After switching to Tremfya after receiving 28 weeks of treatment with Humira, patients showed “sustained improvements” in Psoriasis Symptom and Sign Diary (PSSD) and Dermatology Life Quality Index (DLQI) scores at week 100. Specifically, use of the drug resulted in an increase in the number of patients who reported a PSSD score of 0 – meaning the condition had no impact on their quality of life – from 4.2% and 1.1% at week 28 to 32.6% and 18.0% for symptoms and signs respectively after 100 weeks. Additionally, the proportion of patients who scored either 0 or 1 in their DLQI score increased from 14.4% at week 28 to 65.3% at week 100.
The data also revealed that a PSSD score indicating freedom from all symptoms was associated with greater health-related quality of life (HRQoL) improvements than a Psoriasis Area and Severity Index (PASI) score of 100 in moderate to severe psoriasis patients – a widely used metric of efficacy.
Dr Jaime Oliver, Medical Lead for Immunology in EMEA at Janssen Biologics, commented on the data: “The data presented at EADV highlights Janssen’s commitment to developing effective treatments that translate into real-term positive outcomes for patients. This long-term data not only demonstrates the potential for guselkumab to improve psoriasis signs and symptoms which matter most to patients, but also shows the significance of PRO measurement tools when it comes to improving the quality of life for patients living with this debilitating condition.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
